Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Marcelo V. Negrão(The University of Texas MD Anderson Cancer Center), Sandip Pravin Patel(University of California San Diego), Gabriele Minuti(Fondazione IRCCS Istituto Nazionale dei Tumori), Jhanelle E. Gray(Moffitt Cancer Center), Vadeerat Rinsurongkawong(The University of Texas MD Anderson Cancer Center), Collin M. Blakely(City College of San Francisco), Michael J. Dennis(University of San Diego), Minh Truong(The University of Texas MD Anderson Cancer Center), So Yeon Kim(New Haven Public Schools), Petros Christopoulos(Thorax Foundation), Qi Wang(Tongji University), J. Kevin Hicks(Moffitt Cancer Center), Neal S. Akhave(The University of Texas MD Anderson Cancer Center), Albrecht Stenzinger(Heidelberg University), Sarah B. Goldberg(Yale University), Waree Rinsurongkawong(The University of Texas MD Anderson Cancer Center), Biagio Ricciuti(Harvard University), Paolo Bironzo(University of Turin), Yun Qing(The University of Texas MD Anderson Cancer Center), Christine M. Bestvina(University of Chicago Medicine Comprehensive Cancer Center), Susan C. Scott(Johns Hopkins University), Giannis Mountzios(Henry Dunant Hospital), Matthias Scheffler(TH Köln - University of Applied Sciences), Lukas Delasos(Cleveland Clinic), Alissa J. Cooper(Massachusetts General Hospital), Mingjia Li(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Richard Lee(The University of Texas MD Anderson Cancer Center), Ara A. Vaporciyan(The University of Texas MD Anderson Cancer Center), Subba R. Digumarthy(Massachusetts General Hospital), Jacobi Hines(Northwestern University), Kristen A. Marrone(Johns Hopkins University), Mihaela Aldea(Institut Gustave Roussy), Jacqueline V. Aredo(Stanford University), Lorenza Landi(Tumori Foundation), Mizuki Nishino(Brigham and Women's Hospital), Shu-Chi Tseng(Dana-Farber Brigham Cancer Center), Catherine A. Shu(Columbia University Irving Medical Center), George R. Blumenschein(The University of Texas MD Anderson Cancer Center), Giuseppe Lamberti(Dana-Farber Cancer Institute), Jonathan W. Riess(Comprehensive Blood & Cancer Center), Joao V. Alessi(Hospital Sírio-Libanês), Turja Chakrabarti(University of California, San Francisco), Ying Ni(Beijing Normal University), Dwight H. Owen(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Marina Chiara Garassino(University of Chicago), Blerina Resuli(Tumori Foundation), Jianjun Zhang(The University of Texas MD Anderson Cancer Center), Haniel A. Araújo(The University of Texas MD Anderson Cancer Center), Jing Wang(The University of Texas MD Anderson Cancer Center), Teng Zhou(The University of Texas MD Anderson Cancer Center)
Cited by 181
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k